UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 288

Sortiert nach

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Molecular cancer therapeutics, 2018-05, Vol.17 (5), p.885-896

2018

Link zum Volltext

Verfügbarkeit prüfen

Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors

Cancer research (Chicago, Ill.), 2018-06, Vol.78 (12), p.3267-3279

2018

Link zum Volltext

Verfügbarkeit prüfen

Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model

Cancer research (Chicago, Ill.), 2012-09, Vol.72 (17), p.4483-4493

2012

Link zum Volltext

Verfügbarkeit prüfen

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles

Molecular cancer therapeutics, 2017-06, Vol.16 (6), p.1031-1040

2017

Link zum Volltext

Verfügbarkeit prüfen

Challenges and Opportunities in Cancer Drug Resistance

Chemical reviews, 2021-03, Vol.121 (6), p.3297-3351

2021

Link zum Volltext

Verfügbarkeit prüfen

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma

Molecular cancer therapeutics, 2019-05, Vol.18 (5), p.909-919

2019

Link zum Volltext

Verfügbarkeit prüfen

Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response

Disease models & mechanisms, 2018-11, Vol.11 (11)

2018

Link zum Volltext

Verfügbarkeit prüfen

Modulation of oxidative stress by twist oncoproteins

PloS one, 2013-08, Vol.8 (8), p.e72490

2013

Link zum Volltext

Verfügbarkeit prüfen

Simplification, not “tropicalization”, of temperate marine ecosystems under ocean warming and acidification

Global change biology, 2021-10, Vol.27 (19), p.4771-4784

2021

Link zum Volltext

Verfügbarkeit prüfen

Lymphotoxin signaling is initiated by the viral polymerase in HCV-linked tumorigenesis

PLoS pathogens, 2013-03, Vol.9 (3), p.e1003234-e1003234

2013

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Molecular cancer therapeutics, 2020-11, Vol.19 (11), p.2298-2307

2020

Link zum Volltext

Verfügbarkeit prüfen

Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer

Cancer discovery, 2017-07, Vol.7 (7), p.736-749

2017

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations

Journal of medicinal chemistry, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC

JCI insight, 2022-02, Vol.7 (3)

2022

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis C viral protein NS5A induces EMT and participates in oncogenic transformation of primary hepatocyte precursors

Journal of hepatology, 2012-11, Vol.57 (5), p.1021-1028

2012

Link zum Volltext

Verfügbarkeit prüfen

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance

Journal of medicinal chemistry, 2021-09, Vol.64 (18), p.13704-13718

2021

Link zum Volltext

Verfügbarkeit prüfen

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

NPJ precision oncology, 2022-12, Vol.6 (1), p.95-95, Article 95

2022

Link zum Volltext

Verfügbarkeit prüfen

The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer

Oncotarget, 2012-12, Vol.3 (12), p.1483-1484

2012

Link zum Volltext

Verfügbarkeit prüfen

B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer

Cancer research (Chicago, Ill.), 2012-09, Vol.72 (18), p.4765-4776

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 916: A screen to target EGFR (C797S) in osimertinib-resistant lung cancer identifies brigatinib-based combinations that synergistically inhibit cell growth

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.916-916

2018

Link zum Volltext

Verfügbarkeit prüfen

Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells

Cancer research communications, 2022-10, Vol.2 (10), p.1312-1325

2022

Link zum Volltext

Verfügbarkeit prüfen

Preclinical and Early Phase 1 Clinical Data of AZD2811 Nanoparticle in AML, an Aurora B Kinase Inhibitor

Blood, 2017-12, Vol.130, p.1368-1368

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2079: Osimertinib, an irreversible mutant selective EGFR tyrosine kinase inhibitor, exerts anti tumor activity in NSCLC harbouring exon 20 insertion mutant-EGFR

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2079-2079

2017

Link zum Volltext

Verfügbarkeit prüfen

Cell shape and TGF-β signaling define the choice of lineage during in vitro differentiation of mouse primary hepatic precursors

Journal of cellular physiology, 2010-10, Vol.225 (1), p.186-195

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 288

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(264)
Mit Volltextzugriff
(282)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors

Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles

Challenges and Opportunities in Cancer Drug Resistance

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma

Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response

Modulation of oxidative stress by twist oncoproteins

Simplification, not “tropicalization”, of temperate marine ecosystems under ocean warming and acidification

Lymphotoxin signaling is initiated by the viral polymerase in HCV-linked tumorigenesis

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer

Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations

Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC

Hepatitis C viral protein NS5A induces EMT and participates in oncogenic transformation of primary hepatocyte precursors

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer

B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer

BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors

Abstract 916: A screen to target EGFR (C797S) in osimertinib-resistant lung cancer identifies brigatinib-based combinations that synergistically inhibit cell growth

Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells

Preclinical and Early Phase 1 Clinical Data of AZD2811 Nanoparticle in AML, an Aurora B Kinase Inhibitor

Abstract 2079: Osimertinib, an irreversible mutant selective EGFR tyrosine kinase inhibitor, exerts anti tumor activity in NSCLC harbouring exon 20 insertion mutant-EGFR

Cell shape and TGF-β signaling define the choice of lineage during in vitro differentiation of mouse primary hepatic precursors

Suchergebnisse filtern